Promoter Shailesh Vinodrai Mehta increased his shareholding in Chemkart India Ltd by acquiring 10,800 equity shares on June 24, 2026. The purchase, executed on the open market via BSE Limited, raised his total stake to 1.17% of the company's paid-up equity share capital. The transaction was disclosed to the stock exchange in compliance with Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Prior to the acquisition, Mehta held 1,30,807 equity shares, representing a 1.08% stake. Following the purchase, his holding increased to 1,41,607 shares. The company's total paid-up equity share capital stands at INR 12,09,90,000, comprising 1,20,99,000 equity shares of INR 10 each. The disclosure was submitted to BSE Limited on June 25, 2026.

Shareholding Details

Chemkart India has invested ₹10 lakh in its wholly-owned subsidiary, Vinstar Biotech Private Limited, through a rights issue. The investment was made to support the subsidiary's capital expenditure and working capital requirements.

The company allotted 1,00,000 equity shares with a face value of ₹10 each at an issue price of ₹10 per share. Following this allotment, Chemkart India continues to hold 100% of the shareholding in Vinstar Biotech. The transaction was conducted at arm's length and falls under the ambit of related party transactions.

Vinstar Biotech is an R&D-driven nutraceutical company incorporated in 2023. It specializes in proprietary bioactive technologies and the commercial distribution of health and nutraceutical products. The entity focuses on liposomal and microencapsulated delivery platforms to enhance the bioavailability of health supplements, vitamins, and amino acids.

As of March 31, 2026, Vinstar Biotech reported a turnover of ₹223.43 Lakhs. The entity recorded a loss after tax of ₹24.72 Lakhs and a net worth of negative ₹34.69 Lakhs. The subsidiary had no turnover in the financial years 2023-24 and 2024-25.

Financial Details of Vinstar Biotech